Skip to main navigation Skip to search Skip to main content

Precise druggability of the PTH type 1 receptor

  • Ieva Sutkeviciute
  • , Ji Young Lee
  • , Alex D. White
  • , Christian Santa Maria
  • , Karina A. Peña
  • , Sofya Savransky
  • , Pemra Doruker
  • , Hongchun Li
  • , Saifei Lei
  • , Burak Kaynak
  • , Chialing Tu
  • , Lisa J. Clark
  • , Subramaniam Sanker
  • , Thomas J. Gardella
  • , Wenhan Chang
  • , Ivet Bahar
  • , Jean Pierre Vilardaga
  • University of Pittsburgh
  • University of California at San Francisco
  • Shenzhen Institute of Advanced Technology
  • University of California at Los Angeles
  • Massachusetts General Hospital

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Class B G protein-coupled receptors (GPCRs) are notoriously difficult to target by small molecules because their large orthosteric peptide-binding pocket embedded deep within the transmembrane domain limits the identification and development of nonpeptide small molecule ligands. Using the parathyroid hormone type 1 receptor (PTHR) as a prototypic class B GPCR target, and a combination of molecular dynamics simulations and elastic network model-based methods, we demonstrate that PTHR druggability can be effectively addressed. Here we found a key mechanical site that modulates the collective dynamics of the receptor and used this ensemble of PTHR conformers to identify selective small molecules with strong negative allosteric and biased properties for PTHR signaling in cell and PTH actions in vivo. This study provides a computational pipeline to detect precise druggable sites and identify allosteric modulators of PTHR signaling that could be extended to GPCRs to expedite discoveries of small molecules as novel therapeutic candidates. [Figure not available: see fulltext.].

Original languageEnglish
Pages (from-to)272-280
Number of pages9
JournalNature Chemical Biology
Volume18
Issue number3
DOIs
StatePublished - Mar 2022

Fingerprint

Dive into the research topics of 'Precise druggability of the PTH type 1 receptor'. Together they form a unique fingerprint.

Cite this